Publication: 3492

Publication: 3492

Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance)

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Breast Cancer Res Treat vol 188 (2) 477-487

Year:: 2021
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 10

Parents:: 2148
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:: Health Outcomes

Pharmas:
Grants:: U10CA180821, U10CA180882, UG1CA232760, U10CA180820 and UG1CA189859 (ECOG-ACRIN), U10CA180868 (NSABP/NRG Oncology), UG1CA189821 and U10CA180888 (SWOG)

Corr. Author:
Authors:: Tufia C. Haddad Jun He Ciara C. O'Sullivan Beiyun Chen Donald Northfelt Amylou C. Dueck Karla V. Ballman Kathleen S. Tenner Hannah Linden Joseph A. Sparano Judith O. Hopkins Chamath De Silva Edith A. Perez Paul Haluska Matthew P. Goetz

Networks:: KAISER, LAPS-MN026, NY021, PR028, SCOR

Study: NCCTG-N0733
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: metastatic breast cancer, HER2-positive, insulin-like growth factor receptor, trastuzumab-resistance